Charles L. Sawyers: Research Overview

Dr. Sawyers is an HHMI Investigator searching for molecularly targeted approaches to treat cancer. He has identified cell signaling components critical to the growth of cancer cells in chronic myeloid leukemia, prostate and other cancers, resulting in the development of multiple FDA-approved inhibitors in clinical use today.

Overcoming Resistance to Molecularly Targeted Cancer Therapy

The Sawyers laboratory seeks to understand abnormalities in cancer signaling pathways and translate those insights into more effective therapies. Our early work established a strategy that has continued to guide our research: identifying the molecular drivers of cancer, understanding how resistance to targeted therapies emerges, and using those insights to develop new therapeutic approaches. We began this work in chronic myeloid leukemia (CML), a cancer driven by the BCR-ABL fusion gene, also known as the Philadelphia chromosome translocation. In collaboration with Brian Druker at Oregon Health Sciences University, we developed the ABL kinase inhibitor imatinib (Gleevec) as a primary therapy for patients with CML.

Soon afterward, our group discovered that resistance to imatinib is caused by BCR-ABL kinase domain mutations. Working closely with John Kuriyan’s group, we examined how these mutations alter the structure of the ABL kinase domain. These studies led us to propose that second-generation ABL kinase inhibitors—designed to bind ABL differently from imatinib—might remain active against imatinib-resistant mutants.

In collaboration with scientists at Bristol Myers Squibb, we demonstrated in preclinical models that the dual Src/Abl inhibitor dasatinib has these properties and subsequently co-led its clinical development as a treatment for imatinib-resistant CML. Today, newer generation ABL inhibitors such as asciminib have further improved the outlook for patients with CML.

Prostate Cancer: Initiation, Progression and Mechanisms of Resistance

Building on the strategy established through our work with BCR-ABL, my laboratory has brought this approach to prostate cancer, now the major focus of our research. For more than a decade, our group has worked to define the molecular basis of prostate cancer and uncover the mechanisms by which tumors become resistant to hormone therapy.

A major focus of this work has been the androgen receptor (AR), which continues to play a critical role in disease progression even after tumors reach the hormone-refractory stage. After demonstrating that increased levels of androgen receptor are necessary and sufficient to confer resistance to existing antiandrogens, we collaborated with UCLA chemist Michael Jung to discover enzalutamide, a small-molecule inhibitor that targets the elevated levels of androgen receptor found in hormone-refractory disease through a novel mechanism. Enzalutamide was approved in 2012 for use in men with castration-resistant prostate cancer. We later developed a second AR targeted compound, apalutamide, approved in 2018 to delay prostate cancer metastasis in certain patients at risk for progression.

Our current research continues to address a central challenge in cancer treatment: why tumors become resistant to therapy and how that resistance might be overcome. , now focusing on lineage plasticity as a mechanism of escape from AR blockade, with broad implications beyond prostate cancer.

We also study prostate cancer initiation by driver oncogenes such as MYC, the TMPRSS2-ERG fusion and FOXA1 mutations. This work also focuses on the role of the tumor microenvironment in early disease progression.

To investigate these questions, we have developed several distinctive models of prostate cancer initiation and progression, including genetically defined mouse models, primary prostate organoid cultures and orthotopic organoid transplantation models. More recently, we have combined these experimental systems with single-cell analysis technologies to investigate genetic changes and the interactions between tumor cells and host cells in the prostate.

Together, these studies aim to reveal how prostate cancers initiate and evolve under the selective pressure of treatment—and to use that knowledge to develop more durable therapeutic strategies.


Requests for LAPC4 or LAPC9 cells should be directed to Dr. Robert Reiter at UCLA. For further information, please email Dr. Reiter, at [email protected].

Requests for Myc-CaP cell lines should be directed to ATCC. The order number at ATTC is Myc-CaP cell line (ATCC® CRL- 3255™).


About Charles Sawyers

Charles L. Sawyers received a BA from Princeton University in 1981 and an MD from Johns Hopkins University School of Medicine in 1985, followed by an internal medicine residency at the University of California, San Francisco. He became a Howard Hughes Medical Institute investigator in 2002 while at the University of California, Los Angeles, and then moved to Memorial Sloan Kettering in 2006, where he currently serves as the Chair of the Human Oncology and Pathogenesis Program.

Dr. Sawyers studies mechanisms of cancer drug resistance with an eye toward developing novel therapies. He co-discovered the antiandrogen drug enzalutamide that was approved by the FDA in 2012 for the treatment of advanced prostate cancer. He shared the 2009 Lasker~DeBakey Clinical Medical Research Award for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second-generation ABL inhibitor dasatinib to overcome imatinib resistance. He received the 2013 Breakthrough Prize in Life Sciences, the 2013 Taubman Prize for Excellence in Translational Medical Science, the 2017 American Cancer Society (ACS) Medal of Honor for Clinical Research, the inaugural STAT Biomedical Innovation Award (2019) and the Harrington Prize for Innovation in Medicine (2026).

Dr. Sawyers is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He is past president of the American Association for Cancer Research (AACR) and the American Society of Clinical Investigation, was appointed to the National Cancer Advisory Board by President Obama and served on the Board of Directors of Novartis from 2013-2025. He also serves as Steering Committee Chair of AACR Project GENIE, an international consortium of cancer centers that share genomic and clinical data from patients treated at their respective clinical sites.

Disclosure Statement

Dr. Sawyers serves on the Board of Directors of BeOne Medicines. He is a co-founder of ORIC Pharm and co-inventor of enzalutamide and apalutamide. He is a science advisor to CellCarta, The Column Group, Foghorn Therapeutics, Housey Pharmaceuticals, Juri, Manas AI, Nextech, Nilo, and PMV Pharma.